[{"orgOrder":0,"company":"Wanbang Biopharmaceuticals","sponsor":"Regent Pacific","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"HONG KONG","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Lidocaine","moa":"||Sodium channel alpha subunit","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Wanbang Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Cutaneous Spray","sponsorNew":"Wanbang Biopharmaceuticals \/ Wanbang Biopharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Wanbang Biopharmaceuticals \/ Wanbang Biopharmaceuticals"},{"orgOrder":0,"company":"Wanbang Biopharmaceuticals","sponsor":"Sirona Biochem Corp","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"TFC-039","moa":"SGLT2","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Wanbang Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Wanbang Biopharmaceuticals \/ Wanbang Biopharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Wanbang Biopharmaceuticals \/ Wanbang Biopharmaceuticals"}]

Find Clinical Drug Pipeline Developments & Deals by Wanbang Biopharmaceuticals

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Under the agreement, Wanbang obtained the rights to develop the SGLT2 inhibitor, TFC-039 as a diabetes treatment in China and Sirona retained the global rights. SGLT2 inhibitors provide an opportunity to treat inflicted animals with an oral medication.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          November 23, 2022

                          Lead Product(s) : TFC-039

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Preclinical

                          Recipient : Sirona Biochem Corp

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          02

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Under the License Agreement Regent Pacific is now entitled to receive a payment of approximately HK$6.24 million from Wanbang Pharmaceutical, which is payable within 30 business days. NMPA will now formally review Senstend™ for Clinical Trial Approval.

                          Product Name : Senstend

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          February 12, 2020

                          Lead Product(s) : Lidocaine,Prilocaine

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Approved FDF

                          Recipient : Regent Pacific

                          Deal Size : $4.0 million

                          Deal Type : Licensing Agreement

                          blank

                          03

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Plant Extract/Herbal

                          Upfront Cash : Inapplicable

                          June 23, 2017

                          Lead Product(s) : Dun Ye Guan Xin Ning

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Undisclosed

                          Recipient : Peking University First Hospital

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank